Alnylam Pharmaceuticals ALNY Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's stock-based comp?
- Alnylam Pharmaceuticals (ALNY) reported stock-based comp of $86.63M in Q2 2026.
- How has Alnylam Pharmaceuticals's stock-based comp changed year-over-year?
- Alnylam Pharmaceuticals's stock-based comp decreased by 22.4% year-over-year, from $111.68M to $86.63M.
- What is the long-term trend for Alnylam Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's stock-based comp has grown at a 20.4% compound annual growth rate (CAGR), from $165.72M to $348.24M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.